Minerva Neurosciences, Inc. (NERV)

2.3700 -0.0200 (-0.84%) 收市：04:00PM EDT

Minerva Neurosciences, Inc.

1500 District Avenue
Burlington, MA 01803
United States
617 600 7373
https://www.minervaneurosciences.com

版塊: Healthcare
行業: Biotechnology
全職員工: 9

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Remy Luthringer Ph.D.	Executive Chairman & CEO	1.27M	無	1961
Mr. Geoffrey Robin Race F.C.M.A., M.B.A.	President	913.3k	無	1961
Mr. Frederick W. Ahlholm CPA	Senior VP, CFO & Secretary	726.02k	無	1966
Mr. Joseph Reilly	Senior VP & COO	461k	無	1975
Mr. William B. Boni	Vice President of Investor Relations & Corporate Communications	無	無	1952
Prof. Michael Davidson M.D.	Chief Medical Officer	657.47k	無	1950

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

公司管治

截至 無 止，Minerva Neurosciences, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。